PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 5:26 AM ET

Sponsor Check › Person

TW
No photo found yet (own website and image search run after this page is viewed)

Thomas Woiwode

Named as an officer, director or promoter on SEC Form D filings · CA, Switzerland (as filed: V8) · Jan 6, 2014 → May 9, 2024

25deals (issuers)
$3.83Breported sold
1,031investors
41Form D filings
2014–2024years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:31 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Thomas Woiwode is listed as an executive officer and director on 41 SEC Form D filings by 25 issuers between Jan 2014 and May 2024. Largest by amount reported sold: Versant Venture Capital IX, L.P. (San Francisco, CA — pooled investment fund — 2022–2023; $600.4M reported sold to 82 investors), Versant Venture Capital VII, L.P. (San Francisco, CA — pooled investment fund — 2018; $600M reported sold to 74 investors), Versant Venture Capital VIII, L.P. (San Francisco, CA — pooled investment fund — 2020–2021; $560.2M reported sold to 87 investors), Versant Venture Capital VI, L.P. (San Francisco, CA — pooled investment fund — 2016–2017; $400M reported sold to 57 investors), Versant Voyageurs III, L.P. (San Francisco, CA — pooled investment fund — 2022–2023; $300.2M reported sold to 82 investors) and 20 more (all listed below).

What this means That is a lot of deals — 25 separate companies raised money with this person listed as executive officer and director, over about 10 years. Across those companies the filings report $3.83B sold in total.

Listed alongside Bradley Bolzon (26 shared filings), Jerel Davis (23 shared filings), Clare Ozawa (20 shared filings), Robin Praeger (16 shared filings), Alex Mayweg (13 shared filings) and 86 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Thomas. Each name links to their own page.

17 of the issuers belong to the sponsor group Versant Venture (25 issuers, $3.67B reported sold, 2012–2024).

What this means A sponsor group is one team that sets up a new company for each deal. Versant Venture has 25 companies on file and $3.67B reported sold in total — the group page shows the whole track record in one place.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 1 court case matching the name listed in Key records below.

What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 41 public filings for Thomas Woiwode and found 7 differences, 1 worth asking the sponsor about: 6 Form Ds were filed more than 15 days after the first sale; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Thomas Woiwode has not run yet — it is joining a line of 16,036 names; searches run around the clock at the hosts' allowed rate. Searched so far: 28 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

1 case: 1 dismissed

Pacific Harvest, Inc v. Woiwode dismissed
District Court, D. Hawaii · No. 1:98-cv-00593 · Filed Jul 9, 1998 · Closed Nov 19, 1998 · Nature of suit: 190 Other contract actions
Role of Woiwode: Defendant · Outcome: Terminated 1998-11-19 — FJC Integrated Database disposition: Voluntarily dismissed Docket on CourtListener ↗
same rare surname (3 people in Form D filings, 1 federal dockets); surname only in the caption; court in HI (not a filing state)
What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:31 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Thomas Woiwode..

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:31 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

7 differences found between the filings for Thomas Woiwode — 1 worth asking about (compared 41 filings on Oct 24, 2026)

Worth asking · Dec 5, 2013 – Aug 13, 2019

6 Form Ds were filed more than 15 days after the first sale

Form D filed 491 days after the first sale — Versant Voyageurs I, L.P. · Form D filed 16 days after the first sale — Versant Voyageurs I Feeder, L.P. · Form D filed 19 days after the first sale — Inception IBD, Inc. · Form D filed 16 days after the first sale — Audentes Therapeutics, Inc. · Form D filed 33 days after the first sale — Audentes Therapeutics, Inc. · and 1 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Aug 13, 2019 ↗Versant Voyageurs I, L.P. — PartnerFacts page ↗Form D · Apr 25, 2018 ↗Versant Voyageurs I Feeder, L.P. — PartnerFacts page ↗
Sources
Note · Nov 3, 2016 – Apr 7, 2023

9 offerings changed their target amount between filings

Offering amount changed between filings — Versant Venture Capital IX, L.P. · Offering amount changed between filings — Versant Vantage III, L.P. · Offering amount changed between filings — Versant Voyageurs III, L.P. · Offering amount changed between filings — Versant Voyageurs II, L.P. · Offering amount changed between filings — Versant Venture Capital VIII, L.P. · and 4 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D (earlier) · Oct 12, 2022 ↗Form D/A (later) · Apr 7, 2023 ↗Versant Venture Capital IX, L.P. — PartnerFacts page ↗Form D (earlier) · Oct 11, 2022 ↗
Sources
Note · Aug 17, 2015 – Feb 28, 2023

7 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Santa Ana Bio, Inc. (latest filing Feb 28, 2023) · No amendment in the last 12 months on an offering that may still be open — Santa Ana Bio, Inc. (latest filing Jun 1, 2021) · No amendment in the last 12 months on an offering that may still be open — Jengu Therapeutics, Inc. (latest filing Sep 24, 2020) · No amendment in the last 12 months on an offering that may still be open — Lycia Therapeutics, Inc. (latest filing Mar 17, 2020) · No amendment in the last 12 months on an offering that may still be open — Tempest Therapeutics, Inc. (latest filing Feb 12, 2020) · and 2 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Feb 28, 2023 ↗Santa Ana Bio, Inc. — PartnerFacts page ↗Form D · Jun 1, 2021 ↗Form D · Sep 24, 2020 ↗
Sources
Note · Sep 6, 2019

Same name, different state: "Thomas Street Address 1 Woiwode" (PA) is a separate record

This page covers filings where the address state is CA or V8. A separate record, "Thomas Street Address 1 Woiwode" with address state PA, is listed on 1 filing — most recently by Passage BIO, Inc. (Sep 6, 2019). Both records have filings in the same period (Sep 6, 2019).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Thomas Street Address 1 Woiwode (PA) — PartnerFacts page ↗Form D · Sep 6, 2019 ↗Passage BIO, Inc. — PartnerFacts page ↗Thomas Woiwode (CA,V8) — this page ↗
Sources
Note · Mar 17, 2020 – Sep 16, 2021

Address moved from San Diego, CA to South San Francisco, CA — Lycia Therapeutics, Inc.

The people listed on the Mar 17, 2020 filing give San Diego, CA; on the Sep 16, 2021 filing they give South San Francisco, CA. The address now on file (400 East Jamie Court, Suite 200, South San Francisco, CA) is a registered-agent or shared-office address used by 6 issuers.

What this means A registered agent's address is a mailbox, not where the team works. Ask where the business actually operates.

Form D · Mar 17, 2020 ↗Form D · Sep 16, 2021 ↗Lycia Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Jan 6, 2014 – May 9, 2024

Thomas Woiwode is listed with 2 different address states: CA, V8

CA on 40 filings (Jan 6, 2014 to May 9, 2024); Switzerland (as filed: V8) on 1 filing (Nov 4, 2016).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Jan 6, 2014 ↗Form D · Nov 4, 2016 ↗
Sources
Note · Feb 27, 2019 – Feb 12, 2020

Minimum investment changed between filings — Tempest Therapeutics, Inc.

The Feb 27, 2019 filing lists a minimum of $0; the Feb 12, 2020 Form D/A lists $1.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D/A (earlier) · Feb 27, 2019 ↗Form D/A (later) · Feb 12, 2020 ↗Tempest Therapeutics, Inc. — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

2 of 31 offerings report sales commissions totalling $2,325,000; 0 report finder's fees; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
May 9, 2024 D
Versant Venture Capital SPV I (SAB), L.P.
File 021-512829
$0$0$0None listed on this filingEDGAR ↗
Apr 7, 2023 D/A
Versant Voyageurs III, L.P.
File 021-461406
$0 (est.)$0 (est.)$0J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗EDGAR ↗
Apr 7, 2023 D/A
Versant Vantage III, L.P.
File 021-461398
$0 (est.)$0 (est.)$0J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗EDGAR ↗
Apr 7, 2023 D/A
Versant Venture Capital IX, L.P.
File 021-461417
$0 (est.)$0 (est.)$0J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗EDGAR ↗
Feb 28, 2023 D
Santa Ana Bio, Inc.
File 021-474441
$0$0$0None listed on this filingEDGAR ↗
May 11, 2022 D
Tempest Therapeutics, Inc.
File 021-445321
$0$0$0None listed on this filingEDGAR ↗
Sep 16, 2021 D
Lycia Therapeutics, Inc.
File 021-413559
$0$0$0None listed on this filingEDGAR ↗
Jun 1, 2021 D
Santa Ana Bio, Inc.
File 021-401289
$0$0$0None listed on this filingEDGAR ↗
Apr 15, 2021 D/A
Versant Vantage II, L.P.
File 021-380952
$0 (est.)$0 (est.)$0J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗EDGAR ↗
Apr 15, 2021 D/A
Versant Venture Capital VIII, L.P.
File 021-380948
$0 (est.)$0 (est.)$0J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗EDGAR ↗
Apr 15, 2021 D/A
Versant Voyageurs II, L.P.
File 021-380951
$0 (est.)$0 (est.)$0J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗EDGAR ↗
Mar 2, 2021 D
Vividion Therapeutics, Inc.
File 021-390895
$0$0$0None listed on this filingEDGAR ↗
Sep 24, 2020 D
Jengu Therapeutics, Inc.
File 021-376272
$0$0$0None listed on this filingEDGAR ↗
Mar 17, 2020 D
Lycia Therapeutics, Inc.
File 021-363038
$0$0$0None listed on this filingEDGAR ↗
Feb 12, 2020 D/A
Tempest Therapeutics, Inc.
File 021-306741
$0$0$0None listed on this filingEDGAR ↗
Aug 13, 2019 D
Versant Voyageurs I, L.P.
File 021-346429
$0$0$0
The Issuers' General Partners (or their designees) are entitled to management fees payable by the Issuers.
None listed on this filingEDGAR ↗
May 6, 2019 D
Vividion Therapeutics, Inc.
File 021-338900
$0$0$0None listed on this filingEDGAR ↗
Mar 8, 2019 D
Versant Vantage I, L.P.
File 021-334361
$0$0$0
The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof).
None listed on this filingEDGAR ↗
Dec 17, 2018 D/A
Versant Venture Capital VII, L.P.
File 021-321509
$1,950,000$0$0
The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof).
JP Morgan Securities LLC BrokerCheck CRD 18718 ↗EDGAR ↗
Apr 25, 2018 D
Versant Voyageurs I Feeder, L.P.
File 021-310903
$0$0$0None listed on this filingEDGAR ↗
Jan 3, 2017 D/A
Versant Venture Capital VI, L.P.
File 021-273788
$375,000$0$0
The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof).
J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗
via J.P. Morgan Securities LLC (CRD 79 ↗)
EDGAR ↗
Nov 16, 2016 D
Versant Venture V AIV Feeder Holdings, L.P.
File 021-274614
$0$0$0None listed on this filingEDGAR ↗
Nov 16, 2016 D
Versant Venture V AIV, L.P.
File 021-274607
$0$0$0
The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof).
None listed on this filingEDGAR ↗
Nov 4, 2016 D
CRISPR Therapeutics AG
File 021-273840
$0$0$0None listed on this filingEDGAR ↗
Dec 28, 2015 D
Inception IBD, Inc.
File 021-253915
$0$0$0None listed on this filingEDGAR ↗
Oct 22, 2015 D
Audentes Therapeutics, Inc.
File 021-249874
$0$0$0None listed on this filingEDGAR ↗
Sep 2, 2015 D
Audentes Therapeutics, Inc.
File 021-246838
$0$0$0None listed on this filingEDGAR ↗
Jun 12, 2015 D
Kanyos Bio, Inc.
File 021-241682
$0$0$0None listed on this filingEDGAR ↗
Jun 12, 2015 D
Kanyos Bio, Inc.
File 021-241685
$0$0$0None listed on this filingEDGAR ↗
Dec 24, 2014 D
Audentes Therapeutics, Inc.
File 021-230835
$0$0$0None listed on this filingEDGAR ↗
Jan 6, 2014 D
Euro Ventures 4, Inc.
File 021-209346
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 25

Every issuer that named Thomas Woiwode on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

VV
Pooled Investment Fund · group: Versant Venture

Versant Venture Capital SPV I (SAB), L.P.

San Francisco, CA · May 9, 2024
  • May 9, 2024 · D · $5,000,000 sold of $5,000,000 · 2 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗

Raised $5M from 2 investors (100% of the $5M target) as of the latest filing. Thomas is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Vantage III, L.P.

San Francisco, CA · Oct 11, 2022 → Apr 7, 2023 · 2 filings
  • Apr 7, 2023 · D/A · $298,654,822 sold of $298,654,822 · 82 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗
  • Oct 11, 2022 · D · $0 sold of $250,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗

Raised $298.7M from 82 investors (100% of the $298.7M target) as of the latest filing. Thomas is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(c) (8,096 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Voyageurs III, L.P.

San Francisco, CA · Oct 11, 2022 → Apr 7, 2023 · 2 filings
  • Apr 7, 2023 · D/A · $300,178,571 sold of $300,178,571 · 82 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗
  • Oct 11, 2022 · D · $0 sold of $250,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗

Raised $300.2M from 82 investors (100% of the $300.2M target) as of the latest filing. Thomas is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(c) (8,096 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Venture Capital IX, L.P.

San Francisco, CA · Oct 12, 2022 → Apr 7, 2023 · 2 filings
  • Apr 7, 2023 · D/A · $600,357,143 sold of $600,357,143 · 82 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗
  • Oct 12, 2022 · D · $0 sold of $500,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗

Raised $600.4M from 82 investors (100% of the $600.4M target) as of the latest filing. Thomas is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(c) (8,096 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SA
Biotechnology · group: Versant Venture

Santa Ana Bio, Inc.

Alameda, CA · Jun 1, 2021 → Feb 28, 2023 · 2 filings
  • Feb 28, 2023 · D · $35,313,642 sold of $70,313,642 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 1, 2021 · D · $8,024,658 sold of $42,024,657 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $35.3M from 10 investors (50% of the $70.3M target) as of the latest filing. Thomas is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TT
Biotechnology

Tempest Therapeutics, Inc.

Brisbane, CA · May 11, 2022
  • May 11, 2022 · D · $15,000,000 sold of $15,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $37.2M from 253 investors (100% of the $15M target) as of the latest filing. Thomas is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LT
Biotechnology

Lycia Therapeutics, Inc.

South San Francisco, CA · Mar 17, 2020 → Sep 16, 2021 · 2 filings
  • Sep 16, 2021 · D · $70,055,062 sold of $70,055,062 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 17, 2020 · D · $25,390,410 sold of $50,390,410 · 1 investors · min. $1 · role: Director EDGAR ↗

Raised $106.6M from 16 investors (100% of the $70.1M target) as of the latest filing. Thomas is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Vantage II, L.P.

San Francisco, CA · Nov 18, 2020 → Apr 15, 2021 · 2 filings
  • Apr 15, 2021 · D/A · $253,857,868 sold of $253,857,868 · 52 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗
  • Nov 18, 2020 · D · $0 sold of $225,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗

Raised $253.9M from 52 investors (100% of the $253.9M target) as of the latest filing. Thomas is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(c) (8,096 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Voyageurs II, L.P.

San Francisco, CA · Nov 18, 2020 → Apr 15, 2021 · 2 filings
  • Apr 15, 2021 · D/A · $140,061,224 sold of $140,061,224 · 87 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗
  • Nov 18, 2020 · D · $0 sold of $125,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗

Raised $140.1M from 87 investors (100% of the $140.1M target) as of the latest filing. Thomas is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(c) (8,096 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Venture Capital VIII, L.P.

San Francisco, CA · Nov 18, 2020 → Apr 15, 2021 · 2 filings
  • Apr 15, 2021 · D/A · $560,244,898 sold of $560,244,898 · 87 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗
  • Nov 18, 2020 · D · $0 sold of $475,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the Ultimate General Partner) EDGAR ↗

Raised $560.2M from 87 investors (100% of the $560.2M target) as of the latest filing. Thomas is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(c) (8,096 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VT
Biotechnology

Vividion Therapeutics, Inc.

San Diego, CA · May 6, 2019 → Mar 2, 2021 · 2 filings
  • Mar 2, 2021 · D · $135,000,015 sold of $135,000,015 · 27 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 6, 2019 · D · $82,000,011 sold of $82,000,011 · 20 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $135M from 27 investors (100% of the $135M target) as of the latest filing. Thomas is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

JT
Biotechnology

Jengu Therapeutics, Inc.

San Diego, CA · Sep 24, 2020
  • Sep 24, 2020 · D · $5,000,000 sold of $50,000,000 · 1 investors · min. $1 · role: Director EDGAR ↗

Raised $5M from 1 investor (10% of the $50M target) as of the latest filing. Thomas is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TT
Other Health Care

Tempest Therapeutics, Inc.

South San Francisco, CA · Mar 1, 2018 → Feb 12, 2020 · 3 filings
  • Feb 12, 2020 · D/A · $83,186,733 sold of $100,186,733 · 10 investors · min. $1 · role: Director EDGAR ↗
  • Feb 27, 2019 · D/A · $48,186,738 sold of $70,186,738 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 1, 2018 · D · $25,186,738 sold of $70,186,738 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $83.2M from 10 investors (83% of the $100.2M target) as of the latest filing. Thomas is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Voyageurs I, L.P.

San Francisco, CA · Aug 13, 2019
  • Aug 13, 2019 · D · $102,244,490 sold of $102,244,490 · 14 investors · min. No minimum reported · role: Director (Manager of the General Partner of the General Partner of Parallel) EDGAR ↗

Raised $102.2M from 14 investors (100% of the $102.2M target) as of the latest filing. Thomas is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Vantage I, L.P.

San Francisco, CA · Mar 8, 2019
  • Mar 8, 2019 · D · $0 sold of $150,000,000 · 0 investors · min. No minimum reported · role: Director (Manager of the General Partner of the General Partner of the Issuer) EDGAR ↗

No sales reported yet as of the latest filing. Thomas is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Venture Capital VII, L.P.

San Francisco, CA · Sep 17, 2018 → Dec 17, 2018 · 2 filings
  • Dec 17, 2018 · D/A · $600,000,000 sold of $600,000,000 · 74 investors · min. No minimum reported · role: Director (Manager of the General Partner of the General Partner of the Issuer) EDGAR ↗
  • Sep 17, 2018 · D · $0 sold of $500,000,000 · 0 investors · min. No minimum reported · role: Director (Manager of the General Partner of the General Partner of the Issuer) EDGAR ↗

Raised $600M from 74 investors (100% of the $600M target) as of the latest filing. Thomas is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Voyageurs I Feeder, L.P.

San Francisco, CA · Apr 25, 2018
  • Apr 25, 2018 · D · $20,000,000 sold of $20,000,000 · 1 investors · min. No minimum reported · role: Director (Manager of the General Partner of the General Partner of the General Partner of the Issuer) EDGAR ↗

Raised $20M from 1 investor (100% of the $20M target) as of the latest filing. Thomas is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Venture Capital VI, L.P.

San Francisco, CA · Nov 3, 2016 → Jan 3, 2017 · 2 filings
  • Jan 3, 2017 · D/A · $400,000,000 sold of $400,000,000 · 57 investors · min. No minimum reported · role: Director (Manager of the General Partner of the General Partner of the Issuer) EDGAR ↗
  • Nov 3, 2016 · D · $0 sold of $350,000,000 · 0 investors · min. No minimum reported · role: Director (Manager of the General Partner of the General Partner of the Issuers) EDGAR ↗

Raised $400M from 57 investors (100% of the $400M target) as of the latest filing. Thomas is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Venture V AIV Feeder Holdings, L.P.

San Francisco, CA · Nov 16, 2016
  • Nov 16, 2016 · D · $5,342,623 sold of $5,342,623 · 7 investors · min. No minimum reported · role: Director (Manager of the General Partner of the Issuer) EDGAR ↗

Raised $5.34M from 7 investors (100% of the $5.34M target) as of the latest filing. Thomas is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VV
Pooled Investment Fund · group: Versant Venture

Versant Venture V AIV, L.P.

San Francisco, CA · Nov 16, 2016
  • Nov 16, 2016 · D · $21,939,788 sold of $21,939,788 · 32 investors · min. No minimum reported · role: Director (Manager of the General Partner of the Issuer) EDGAR ↗

Raised $21.9M from 32 investors (100% of the $21.9M target) as of the latest filing. Thomas is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

CT
Biotechnology

CRISPR Therapeutics AG

Zug, Switzerland (as filed: V8) · Nov 4, 2016
  • Nov 4, 2016 · D · $35,000,000 sold of $35,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $35M from 1 investor (100% of the $35M target) as of the latest filing. Thomas is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(c) (163 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

II
Pharmaceuticals · group: Versant Venture

Inception IBD, Inc.

San Diego, CA · Dec 28, 2015
  • Dec 28, 2015 · D · $6,919,018 sold of $19,139,018 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6.92M from 8 investors (36% of the $19.1M target) as of the latest filing. Thomas is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AT
Biotechnology

Audentes Therapeutics, Inc.

San Francisco, CA · Dec 24, 2014 → Oct 22, 2015 · 3 filings
  • Oct 22, 2015 · D · $64,999,949 sold of $64,999,949 · 27 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 2, 2015 · D · $0 sold of Indefinite · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 24, 2014 · D · $42,500,002 sold of $42,500,002 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $65M from 27 investors (100% of the $65M target) as of the latest filing. Thomas is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

KB
Biotechnology

Kanyos Bio, Inc.

San Francisco, CA · Jun 12, 2015 → Jun 12, 2015 · 2 filings
  • Jun 12, 2015 · D · $6,009,268 sold of $6,009,268 · 17 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 12, 2015 · D · $10,399,876 sold of $10,399,876 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $10.4M from 17 investors (100% of the $6.01M target) as of the latest filing. Thomas is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

EV
Other · group: Versant Venture

Euro Ventures 4, Inc.

Menlo Park, CA · Jan 6, 2014
  • Jan 6, 2014 · D · $1,000,000 sold of $1,000,000 · 2 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $1M from 2 investors (100% of the $1M target) as of the latest filing. Thomas is listed as executive officer, director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other pages with the same name (1)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

People around Thomas 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

VV
Management entity

Versant Ventures VI GP, L.P.

Director · 4 shared filings (3 issuers)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Ventures VI GP-GP, LLC

Director · 4 shared filings (3 issuers)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Ventures VII GP-GP, LLC

Director, Executive Officer · 3 shared filings (2 issuers)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Ventures VII GP, L.P.

Director, Executive Officer · 3 shared filings (2 issuers)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Ventures V, LLC

Director · 2 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Voyageurs I GP Company

Director, Promoter · 2 shared filings (2 issuers)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Vantage II GP, L.P.

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Vantage II GP-GP, LLC

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Voyageurs II GP-GP, LLC

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Voyageurs II GP, L.P.

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Ventures VIII GP-GP, LLC

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Ventures VIII GP, L.P.

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Ventures IX GP, L.P.

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Ventures IX GP-GP, LLC

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Voyageurs III GP, L.P.

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Voyageurs III GP-GP, LLC

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Vantage III GP, L.P.

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Vantage III GP-GP, LLC

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

AC
Management entity

Anthony Coles

Director · 1 shared filing (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Vantage I GP-GP, LLC

Director · 1 shared filing (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

VV
Management entity

Versant Vantage I GP, L.P.

Director · 1 shared filing (1 issuer)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

BB
No photo found yet (own website and image search run after this page is viewed)
Person

Bradley Bolzon

Director, Executive Officer · 26 shared filings (17 issuers) · also on 14 other issuers

Bradley Bolzon is on 31 issuers in total — a repeat sponsor. Their page lists every one.

JD
No photo found yet (own website and image search run after this page is viewed)
Person

Jerel Davis

Director, Executive Officer · 23 shared filings (14 issuers) · also on 9 other issuers

Jerel Davis is on 23 issuers in total — a repeat sponsor. Their page lists every one.

CO
No photo found yet (own website and image search run after this page is viewed)
Person

Clare Ozawa

Executive Officer, Director · 20 shared filings (12 issuers) · also on 4 other issuers

Clare Ozawa is on 16 issuers in total — a repeat sponsor. Their page lists every one.

RP
No photo found yet (own website and image search run after this page is viewed)
Person

Robin Praeger

Director, Executive Officer · 16 shared filings (11 issuers) · also on 1 other issuer

Robin Praeger is on 12 issuers in total — a repeat sponsor. Their page lists every one.

AM
No photo found yet (own website and image search run after this page is viewed)
Person

Alex Mayweg

Executive Officer · 13 shared filings (7 issuers)

Alex Mayweg is on 7 issuers in total — a repeat sponsor. Their page lists every one.

CR
No photo found yet (own website and image search run after this page is viewed)
Person

Carlo Rizzuto

Executive Officer · 6 shared filings (3 issuers) · also on 3 other issuers

Carlo Rizzuto is on 6 issuers in total — a repeat sponsor. Their page lists every one.

KN
No photo found yet (own website and image search run after this page is viewed)
Person

Kirk Nielsen

Director · 6 shared filings (5 issuers) · also on 20 other issuers

Kirk Nielsen is on 25 issuers in total — a repeat sponsor. Their page lists every one.

PP
No photo found yet (own website and image search run after this page is viewed)
Person

Petpiboon Prasit

Executive Officer, Director · 4 shared filings (2 issuers) · also on 5 other issuers

Petpiboon Prasit is on 7 issuers in total — a repeat sponsor. Their page lists every one.

TD
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas W. Dubensky, Jr.

Executive Officer, Director · 4 shared filings (2 issuers)

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

MP
No photo found yet (own website and image search run after this page is viewed)
Person

Matthew Patterson

Executive Officer, Director · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

RW
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Weisskoff

Director · 3 shared filings (1 issuer) · also on 17 other issuers

Robert Weisskoff is on 18 issuers in total — a repeat sponsor. Their page lists every one.

JS
No photo found yet (own website and image search run after this page is viewed)
Person

Jonathan T. Silverstein

Director · 3 shared filings (1 issuer) · also on 32 other issuers

Jonathan T. Silverstein is on 33 issuers in total — a repeat sponsor. Their page lists every one.

JL
No photo found yet (own website and image search run after this page is viewed)
Person

Jonathan Leff

Director · 3 shared filings (1 issuer) · also on 12 other issuers

Jonathan Leff is on 13 issuers in total — a repeat sponsor. Their page lists every one.

TS
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas Schuetz

Director · 3 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Thomas Woiwode. Their page shows their other deals.

The team behind the deals

VV
Sponsor group

Versant Venture

25 issuers · 36 filings · $3.67B reported sold · 2012–2024

One team, 25 deal companies. Thomas Woiwode is listed on 17 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Thomas Woiwode.

Same business address

51 other issuers file from the same address (first 50 shown)

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

None of the 25 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Thomas Woiwode by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 25 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Thomas Woiwode is listed on: none on file. No website or social profile named in Versant Voyageurs I, L.P.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #231,152 of 374,652 in line (14 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (San Francisco, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Thomas Woiwode appears on a new Form D, or when a court case or SEC action is matched to them. See plans →